Moreover, it was shown that the depletion of FTO by CRISPR/cas9 has no effect on AML growth [51] and the Project DRIVE, a large-scale knockdown screening in cancer cell lines, detected no general FTO-dependency of leukaemia cells [64]. This evidence concerns the gene FTO and acute myeloid leukemia.